FluMist(R) Now Available for the 2004-2005 Flu Season
submited by kickingbird at Oct, 8, 2004 9:6 AM from MedImmune
FluMist will be available this flu season for $16.00 wholesale per non- returnable dose or $23.50 wholesale per returnable dose -- reflecting a price drop of 50 percent or more compared to the 2003-2004 season. For more information about FluMist, visit http://www.FluMist.com. Physicians, pharmacists and other healthcare professionals interested in ordering FluMist may call (877) FLUMIST.
FluMist is the first live, attenuated influenza vaccine indicated for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, 5 to 17 years of age, and healthy adults, 18 to 49 years of age.
There are risks associated with all vaccines, including FluMist. FluMist does not protect 100-percent of individuals vaccinated, or may not protect against viral strains not represented in the vaccine. FluMist is contraindicated in persons with hypersensitivity to any component of the vaccine, including eggs; in children and adolescents receiving aspirin therapy or aspirin-containing therapy; in individuals with a history of Guillain-Barre syndrome; and in individuals with known or suspected immune deficiency. The safety and efficacy of FluMist have not been established in pregnant women or for patients with chronic underlying medical conditions, including asthma or reactive airways disease; the vaccine should not be administered to these patients. See Prescribing Information for indications and usage, dosage and administration and safety information.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of pediatric infectious diseases, cancer and inflammatory diseases. With approximately 1,900 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company´s website at http://www.medimmune.com.
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management´s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company´s filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.
Source: MedImmune, Inc.
- WOAH: Influenza A viruses of high pathogenicity (Infection with H5N1) (non-poultry including wild birds) (2017-), China 13 days ago
- China: Confirmed human case of avian influenza A(H9N2) reported in Sichuan province Jun, 29, 2022
- China: A human case of avian influenza A(H5N6) reported in Jiangxi province Jun, 27, 2022
- China: Confirmed human cases of avian influenza A(H9N2) reported in Hunan and Guizhou province Jun, 9, 2022
- China: Confirmed human case of avian influenza A(H3N8) reported in Hunan province Jun, 1, 2022